Efficacy and safety of ASP0819 in patients with fibromyalgia

Takeaway

  • ASP0819 had a good tolerability profile and demonstrated findings suggestive of efficacy in patients with fibromyalgia.

Why this matters ?

  • Fibromyalgia pathophysiology is not fully understood, but peripheral processes including C-fiber hyperexcitability are thought to be involved, and while treatments are typically opioid-based, non-opioid agents targeting these mechanisms, such as ASP0819, may be beneficial.

  • The tolerability and efficacy of ASP0819 raises the potential of novel non-opioid treatment options for fibromyalgia patients which may be beneficial given opioid-associated risks for addiction and overdose, as well as lack of evidence of their efficacy in treating fibromyalgia.